Mr. Wilmer Tirado, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 9374 Sw 173rd Ter, Palmetto Bay, FL 33157 Phone: 305-213-9241 |
Lyndia Charles, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 17540 Sw 93rd Pl, Palmetto Bay, FL 33157 Phone: 786-566-6670 |
Dr. Gabriela Kibort, PHARM,D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 15043 S Dixie Hwy, Palmetto Bay, FL 33176 Phone: 786-573-5177 |
News Archive
Landec Corporation, a materials science company that develops and markets patented polymer products for food, agriculture, personal care and drug delivery applications, today announced that it has acquired Lifecore Biomedical, Inc. from Warburg Pincus Private Equity IX, LP. When acquired by Warburg Pincus in March 2008, Lifecore was comprised of two divisions, the Dental Division and the Hyaluronan Division. The Dental Division was merged into a Warburg Pincus portfolio company.
In the past five years, the number of lung transplantations carried out has increased by about 20%. In the end stage of various lung diseases, transplantation is the last remaining option for treatment, and it can both prolong life and improve its quality.
Patients with Parkinson's disease, particularly those with excessive daytime sleepiness, have reduced melatonin levels and amplitude of the melatonin circadian rhythm, research shows.
Revolutions Medical Corporation, producers of the RevVac safety syringe, RevColor, RevDisplay and Rev3D MRI Technology, announced today that recent mass media reports that CT scans cause cancer could rapidly elevate MRI as the technology of choice for musculoskeletal scans and more.
PharmAthene, Inc. a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that the Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority has modified its existing research and development contract with PharmAthene providing for up to a total of $78.4 million in additional funding, provided that certain milestones are achieved and that all contract options and extensions are exercised by the government, to support the continued advanced development of SparVax™, a second generation recombinant protective antigen (rPA) anthrax vaccine targeted for future procurement in the U.S. Strategic National Stockpile.
› Verified 1 days ago